

# LITERATURA

1. Adrogué HJ, Madias NE. Hyponatremia. *New Engl J Med*. 2000;342:1581–9.
2. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. *Orphanet J Rare Dis*. 2010;5:9. doi:10.1186/1750-1172-5-9.
3. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et al.; United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. *J Clin Endocrinol Metab*. 2010;95(11):5110–21.
4. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. *Eur J Endocrinol*. 2008;158:273–85.
5. Braunstein GD. Hypothalamic Syndromes. In: Jameson JL, DeGroot LJ. *Endocrinology*. 6th ed. W. B. Saunders; 2010. p. 230–342.
6. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? *Eur J Endocrinol*. 2009;161:513–27.
7. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. *Am J Clin Pathol*. 2009;132:658–65.
8. Cooper TG et al. World Health Organization reference values for human semen characteristics. *Human Reproduction Update*. 2010;16(3):231–45.
9. Čáp J, Uzel štítné žlázy. *Klin Farmakol Farm*. 2011;25(1):28–32.
10. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liège, Belgium. *J Clin Endocrinol Metab*. 2006;91:4769–75.
11. Dauber A, Kellogg M, Majzoub JA. Monitoring of Therapy in Congenital Adrenal Hyperplasia. *Clin Chem*. 2010;56(8):1245–51.
12. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community based, cross-sectional study in Banbury (Oxfordshire). *Clin Endocrinol (Oxf)*. 2010;72:377–82.
13. Ferriman DM, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol*. 1961;21:1440–7.
14. Fisseler-Eckhoff A, Demes M. Neuroendocrine Tumors of the Lung. *Cancers*. 2012;4:777–98.
15. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2008;93:3266–81.
16. Hána V. *Hypopituitarismus a diabetes insipidus centralis*. Praha: Maxdorf; 2011.
17. Harris PE, Bouloux PMG. *Endocrinology in clinical practice*. CRC Press; 2014.

18. Jameson JL, DeGroot LJ. *Endocrinology*, 6th edition, W.B. Saunders Company, 2010.
19. Kaltsas G. et al. *Trends in endocrinology and metabolism*, 2012;23(12):602-9.
20. Kasper DL, Braunwald E, Fauci AS, et al., editors. *Harrison's Principles of Internal Medicine*. 16th ed. McGraw Hill; 2005.
21. Katznelson L et al. Global clinical response in Cushing's syndrome patients treated with mifepristone. *Clin Endo*. 2014;80:562-9.
22. Katznelson, L, Atkinson, JL, Cook, DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. *Endocrine Pract*. 2011;17 Suppl 4:1-44.
23. Khan AA, Bilezikian JP, Potts JT Jr. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. On behalf of the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. *J Clin Endocrinol Metab*. 2009;94:333-4.
24. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. *Williams Textbook of Endocrinology*. 10th ed. Philadelphia: W. B. Saunders; 2003.
25. Lebl et al. *Klinická pediatrie*, Galén 2012.
26. Loh JA, Verbalis JG. Disorders of Water and Salt Metabolism Associated with Pituitary Disease. *Endocrinol Metab Clin N Am*. 2008;37:213-34.
27. Marek J, editor et al. *Farmakoterapie vnitřních nemocí*. 4th ed. Praha: Grada; 2010.
28. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. *J Clin Endocrinol Metab*. 2002;87(5):1941-6.
29. Phyllis W. Speiser, Ricardo Azziz, Laurence S. Baskin, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2010;95(9):4133-60.
30. Smith DM, McKenna K, Thompson CJ. Hyponatremia. *Clin Endocrinol (Oxf)*. 2000;52:668-78.
31. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Europ J Endocrinol*. 2014;170:G1-47.
32. Terzolo M, Stigliano A, Chiodini I, et al. AME Position Statement on adrenal incidentaloma. *Eur J Endocrinol*. 2011;164:851-70.
33. Whitaker MJ, Debono M, Huatan H, Merke DP, Arlt W, Ross RJ. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. *Clin Endocrinol (Oxf)*. 2014;80(4):554-61.
34. Wilson JD, Foster DW. *Williams Textbook of Endocrinology*. 10th ed. W. B. Saunders; 2003.
35. Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol*. 2007;66:607-18.
36. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. *J Clin Endocrinol Metab*. 2011;96(7):2004-15.